Switch from intravenous to subcutaneous immunoglobulin in CIDP and MMN: improved tolerability and patient satisfaction.
about
Subcutaneous immunoglobulins in the treatment of chronic immune-mediated neuropathiesImpact of Immunoglobulin Therapy in Pediatric Disease: a Review of Immune Mechanisms.Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial.Drugs for the treatment of peripheral neuropathies.Novel immunotherapeutic strategies in chronic inflammatory demyelinating polyneuropathy.Clinical experiences in primary and secondary immunodeficiencies and immune-mediated conditions using Gammanorm(®).Subcutaneous versus intravenous immunoglobulin for chronic autoimmune neuropathies: A meta-analysis.The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study.Subcutaneous immunoglobulin for treatment of multifocal motor neuropathy.Subcutaneous immunoglobulin as first-line therapy in treatment-naive patients with chronic inflammatory demyelinating polyneuropathy: randomized controlled trial study.Improvement of hemoglobin levels after a switch from intravenous to subcutaneous administration of immunoglobulin in chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy.Headache and Nausea after Treatment with High-Dose Subcutaneous versus Intravenous Immunoglobulin.
P2860
Q26745685-47AACFF3-0DBF-4CFA-9C05-2F8DFFCF305EQ30252123-82506626-BDE1-4301-82F8-C6FC02AB0B59Q37125900-0F69F2E2-EEBD-4958-9578-B05EC1759800Q38633190-70F778B9-9AD5-4987-8750-379A0C968DA3Q38711142-F1D1435C-1375-408A-B107-75EAE9E51F5CQ39217483-263719F0-E222-42EF-AE1C-BF10CE898E28Q39370917-499427E4-5497-47F3-9E86-E79D1763B227Q47673920-40C22CCD-8323-403A-AEBB-F84D2472981CQ51134410-53C696FE-9422-4CED-90C1-8D46D206726BQ51246055-6FA802F2-E022-47A1-A787-E8B74F85B902Q51649208-33127831-1C05-4A59-AB3C-4A6F1519C8BEQ53459363-FBB1DB42-9D17-4524-AF28-26F3D174E8B8
P2860
Switch from intravenous to subcutaneous immunoglobulin in CIDP and MMN: improved tolerability and patient satisfaction.
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Switch from intravenous to sub ...... lity and patient satisfaction.
@ast
Switch from intravenous to sub ...... lity and patient satisfaction.
@en
Switch from intravenous to sub ...... lity and patient satisfaction.
@nl
type
label
Switch from intravenous to sub ...... lity and patient satisfaction.
@ast
Switch from intravenous to sub ...... lity and patient satisfaction.
@en
Switch from intravenous to sub ...... lity and patient satisfaction.
@nl
prefLabel
Switch from intravenous to sub ...... lity and patient satisfaction.
@ast
Switch from intravenous to sub ...... lity and patient satisfaction.
@en
Switch from intravenous to sub ...... lity and patient satisfaction.
@nl
P2860
P356
P1476
Switch from intravenous to sub ...... lity and patient satisfaction.
@en
P2093
Fabrizio Marreno
Robert D M Hadden
P2860
P356
10.1177/1756285614563056
P577
2015-01-01T00:00:00Z